Icotinib as Adjuvant Therapy in Treating Non-small-cell Lung Cancer Patients With Positive EGFR Mutation

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2013
This study is designed to evaluate the efficacy of icotinib as adjuvant therapy in treating such patients. The primary endpoint is to compare the recurrence-free survival after 1-year or 2-year treatment with icotinib.
Epistemonikos ID: 10b59c5c13c4292a62415f041092ee85f74caf24
First added on: May 11, 2024